Ascendis Pharma initiates clinical trial of dwarfism drug
Danish biotech company Ascendis Pharma’s achondroplasia treatment, Transcon CNP, will be clinically tested across six sites in China.
by MIKKEL AABENHUS HEMMINGSEN, translated by daniel pedersen
Ascendis Pharma has initiated a hunt for new patients for a phase II trial in China, according to the Clinical Trials database.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Biomarin projects 2022 Voxzogo sales of USD 115m
For subscribers
